Medicare beneficiaries who spend heavily on prescription drugs will hit a hard annual ceiling of $2,400 in out-of-pocket costs starting in 2027, after which their share of covered drug expenses drops to zero. The cap, set by the Contract Year 2027 Medicare Advantage and Part D Final Rule, locks in a key piece of the Inflation Reduction Act’s redesign of the Part D benefit. For enrollees taking expensive specialty medications or managing multiple chronic conditions, the change replaces an older structure that left many paying thousands more each year with no guaranteed stopping point.
Why the $2,400 Part D cap changes household math in 2027
The 2027 threshold works differently from the benefit design that existed before the IRA-driven overhaul. Under prior rules, Medicare Part D had four coverage stages, and enrollees who reached the catastrophic phase still owed 5 percent of drug costs indefinitely. That open-ended exposure hit hardest among people taking biologics, cancer treatments, or other high-cost therapies, where 5 percent of a single fill could run into hundreds of dollars per month. The redesigned benefit eliminates that tail risk entirely. Once a beneficiary’s qualifying out-of-pocket spending reaches $2,400 in a plan year, cost sharing in the catastrophic phase falls to $0 under federal statute.
The same redesign removes the coverage gap, sometimes called the “donut hole,” which had been a separate cost stage between initial coverage and catastrophic coverage. With that phase gone, the path from deductible to the $2,400 ceiling becomes more straightforward, though individual plans still set their own formulary tiers, copays, and coinsurance rates within federal guardrails. Current Medicare materials on Part D drug costs describe the traditional progression through deductible, initial coverage, and catastrophic protection; in 2027, that progression will be simplified and capped by the new out-of-pocket maximum.
A practical question looms behind the structural improvement: how will Part D plan sponsors absorb the added liability they now carry once enrollees cross the threshold earlier in the year? Plans that previously shared catastrophic-phase costs with beneficiaries must now cover 100 percent of those expenses above the cap. In regions where average Part D spending runs higher, driven by older populations or greater use of specialty drugs, insurers face steeper per-member costs. That pressure creates a direct incentive to adjust 2027 base premiums, tighten formularies, or steer enrollees toward lower-cost alternatives. The CY 2027 final rule outlines updated payment policies and risk-adjustment refinements meant to soften the blow, but whether those adjustments fully offset the new plan liabilities remains an open question heading into the fall enrollment season.
CMS parameters and the legal framework behind the 2027 threshold
The $2,400 figure for plan years ending in 2027 appears in the official cost threshold and cost limit amounts that CMS posts for the Retiree Drug Subsidy program. In that notice, CMS lists the deductible, initial coverage limit, and out-of-pocket threshold that define the Part D benefit for that year, including the new maximum on beneficiary spending. By specifying these parameters, the agency gives Part D sponsors a blueprint for structuring premiums and cost sharing around the statutory cap. The 2027 announcement on cost thresholds confirms that once enrollees reach $2,400 in true out-of-pocket spending, plans and Medicare, rather than beneficiaries, assume full financial responsibility for covered drugs.
The annual out-of-pocket threshold framework itself is codified in 42 U.S.C. Section 1395w-102, which defines how Part D benefits are structured and establishes the statutory basis for zero beneficiary cost sharing once the threshold is met. That section lays out the mechanics of the standard benefit, including how deductibles, coinsurance, and the catastrophic phase interact. The Inflation Reduction Act amended this framework to replace the prior open-ended catastrophic obligation with a firm ceiling on what beneficiaries can be asked to pay.
In practice, plans must align their 2027 benefit designs with both the statute and CMS guidance. The final rule for 2027 clarifies how plan liability is split with the federal reinsurance program above the cap, as well as how low-income subsidy enrollees are treated under the new structure. It also interacts with other Inflation Reduction Act provisions, such as limits on annual premium growth and phased-in manufacturer discounts, which together shape the financial environment in which the $2,400 threshold operates.
What beneficiaries should watch as 2027 approaches
For individual Medicare beneficiaries, the headline takeaway is straightforward: starting in 2027, there is a clear, predictable stopping point for Part D out-of-pocket spending. People who currently rely on high-cost medications can expect their annual drug bills to fall once they hit the $2,400 mark, with no more 5 percent coinsurance in the catastrophic phase. That change is especially significant for those on fixed incomes or with multiple chronic conditions, who have historically faced difficult trade-offs between adherence and affordability late in the year.
Still, the new protection does not eliminate the need to compare plans carefully. Premiums, deductibles, and formulary rules will continue to vary, and plans may respond to their higher post-threshold liability by tightening utilization management or favoring particular drug classes. Beneficiaries who anticipate crossing the cap should pay attention to how their medications are tiered, whether prior authorization is required, and how smoothly plans coordinate with pharmacies under the new benefit design.
As 2027 nears, CMS is expected to update consumer-facing materials and plan comparison tools to reflect the redesigned Part D structure. The underlying legal and regulatory framework is already in place: a statutory cap on out-of-pocket spending, detailed cost parameters from CMS, and a final rule that directs how plans must implement the change. The remaining work will involve translating those rules into on-the-ground choices for beneficiaries, who will see the impact of the $2,400 ceiling in their monthly pharmacy receipts once the new benefit year begins.
Free tool for readers: Built for Americans 55 to 80: a free, plain-English retirement check. See your Retirement Safety Score — your 0–100 number and a few steps — in about five minutes, no account needed.
